US4681893A
(en)
|
1986-05-30 |
1987-07-21 |
Warner-Lambert Company |
Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
|
US5245047A
(en)
|
1988-02-22 |
1993-09-14 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
US5124482A
(en)
|
1988-02-22 |
1992-06-23 |
Warner-Lambert Company |
Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
|
US5149837A
(en)
|
1988-02-22 |
1992-09-22 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
US5003080A
(en)
|
1988-02-22 |
1991-03-26 |
Warner-Lambert Company |
Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
|
US5097045A
(en)
|
1989-02-01 |
1992-03-17 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
US5216174A
(en)
|
1988-02-22 |
1993-06-01 |
Warner-Lambert Co. |
Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US5103024A
(en)
|
1990-10-17 |
1992-04-07 |
Warner-Lambert Company |
Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
|
US5248793A
(en)
|
1990-10-17 |
1993-09-28 |
Warner-Lambert Company |
Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
|
US5155251A
(en)
|
1991-10-11 |
1992-10-13 |
Warner-Lambert Company |
Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
|
US5213995A
(en)
|
1992-04-16 |
1993-05-25 |
At&T Bell Laboratories |
Method of making an article comprising a periodic heteroepitaxial semiconductor structure
|
ES2133158T3
(es)
|
1993-01-19 |
1999-09-01 |
Warner Lambert Co |
Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
|
US5298627A
(en)
|
1993-03-03 |
1994-03-29 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
CZ294108B6
(cs)
*
|
1995-07-17 |
2004-10-13 |
Warner@Lambertácompany |
Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové
|
HRP960312B1
(en)
|
1995-07-17 |
2001-10-31 |
Warner Lambert Co |
NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
|
HRP960313B1
(en)
*
|
1995-07-17 |
2002-08-31 |
Warner Lambert Co |
Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
US6087511A
(en)
|
1996-07-16 |
2000-07-11 |
Warner-Lambert Company |
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
|
KR100447370B1
(ko)
|
1996-07-29 |
2004-09-08 |
워너-램버트 캄파니 엘엘씨 |
보호된 (s)-3,4-디히드록시부티르산 에스테르의 개선된 제조 방법
|
JP3031257B2
(ja)
*
|
1996-08-01 |
2000-04-10 |
トヨタ自動車株式会社 |
ロックアップクラッチのスリップ制御装置
|
KR100668575B1
(ko)
|
1997-12-19 |
2007-01-17 |
워너-램버트 익스포트 리미티드 |
1,3-디올의 합성방법
|
SI20070A
(sl)
|
1998-09-18 |
2000-04-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Nove soli inhibitorjev HMG-CoA reduktaze
|
IN191236B
(ja)
|
1999-05-25 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
HU226640B1
(en)
|
1999-10-18 |
2009-05-28 |
Egis Gyogyszergyar Nyilvanosan |
Process for producing amorphous atorvastatin calcium salt
|
PT1535613E
(pt)
*
|
1999-11-17 |
2010-10-04 |
Teva Pharma |
Processo de preparação de uma forma polimórfica de atorvastatina de cálcio
|
SI20425A
(sl)
|
1999-12-10 |
2001-06-30 |
LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. |
Priprava amorfnega atorvastatina
|
EP1584616A1
(en)
|
1999-12-17 |
2005-10-12 |
Pfizer Science and Technology Ireland Limited |
Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt
|
KR20080064908A
(ko)
*
|
2000-06-28 |
2008-07-09 |
테바 파마슈티컬 인더스트리즈 리미티드 |
카르베딜올
|
KR100704213B1
(ko)
|
2000-11-03 |
2007-04-10 |
테바 파마슈티컬 인더스트리즈 리미티드 |
아토르바스타틴 헤미-칼슘 vii형
|
KR100877165B1
(ko)
|
2000-11-16 |
2009-01-07 |
테바 파마슈티컬 인더스트리즈 리미티드 |
수산화 칼슘을 이용한[R(R*,R*)]-2-(4-플루오로페닐)-β,δ-디하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1H-피롤-1-헵탄산 에스테르의 가수분해
|
IL156055A0
(en)
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
CA2622697A1
(en)
*
|
2000-12-27 |
2002-07-04 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of atorvastatin
|
US6476235B2
(en)
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
WO2002057228A1
(en)
|
2001-01-17 |
2002-07-25 |
Biocon India Limited |
Atorvastatin calcium
|
WO2002057229A1
(en)
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
SI20814A
(sl)
|
2001-01-23 |
2002-08-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Priprava amorfnega atorvastatina
|
SI20848A
(sl)
|
2001-03-14 |
2002-10-31 |
Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. |
Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
|
IN190564B
(ja)
|
2001-04-11 |
2003-08-09 |
Cadila Heathcare Ltd |
|
GB0111077D0
(en)
|
2001-05-04 |
2001-06-27 |
Biochemie Gmbh |
Organic compounds
|
SK16002003A3
(sk)
|
2001-06-29 |
2004-12-01 |
Warner-Lambert Company Llc |
Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
|
HUP0201083A2
(hu)
*
|
2002-03-28 |
2004-06-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
|
AU2005223491A1
(en)
*
|
2004-03-17 |
2005-09-29 |
Ranbaxy Laboratories Limited |
Crystalline form of atorvastatin hemi calcium
|
CA2649054A1
(en)
*
|
2004-05-05 |
2005-11-10 |
Pfizer Products Inc. |
Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
|